Innovative Cancer Therapies at Boehringer Ingelheim - Pipeline Overview
Discover Boehringer Ingelheim's cutting-edge approach to cancer care through personalized treatments and collaborative research efforts targeting key drivers of cancer. Explore a diverse range of therapeutic approaches aiming to revolutionize cancer treatment for present and future generations.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
LEADING SCIENCE COLLABORATION Boehringer Ingelheim cancer care is personal today and for generations PATIENT FOCUSED COMMITMENT Oncology pipeline overview September 2024 SC-CRP-04579
We aim to address key drivers of cancer and reset the immune archetype with a diverse range of therapeutic approaches and smart combinations Our dual research focus Cancer cell-directed therapies Immuno-oncology therapies Block aberrant cancer cell signaling Activate and redirect T cells to kill tumors Zongertinib, KRAS multi-inhibitor Obrixtamig*, B7-H6/CD3 TcEs Revert oncogenic gene expression Activate tumor-specific T cells Vaccines, oncolytic viruses Transcription factors Brigimadlin, TRAILR2/CDH3 SIRP , STING, CD137/FAP Induce tumor cell death Enhance innate immunity Oncolytic viruses; Bacterial delivery Small molecules Antibody-drug conjugates T-cell engagers Small molecules Cancer vaccines Antibody formats PROTACs PROTACs NOTE: These assets are investigational agents and have not been approved for use. The efficacy and safety of these investigational assets have not been established. 2 * Proposed International nonproprietary name
Selected assets that are being developed to address high unmet patient needs Lung cancer Block aberrant cancer cell signaling Induce tumor cell death Activate and redirect T cells to kill tumors Activate tumor-specific T cells Sarcomas Obrixtamig* DLL3/CD3 T-cell engager Zongertinib HER2 TKI Brigimadlin MDM2-p53 antagonist KISIMA cancer vaccine GI cancers B7-H6/CD3 T-cell engager Example indications, not exhaustive NOTE: These assets are investigational agents and have not been approved for use. The efficacy and safety of these investigational assets have not been established. 3 * Proposed International nonproprietary name
Transforming cancer care requires a diversity of minds Example of pre-clinical collaborations 3T Biosciences TCE platform Memorial Sloan Kettering Cancer Center MD Anderson Cancer Center Phenomic AI KRAS Stroma-rich cancers TRACTION platform University of Dundee CheckmAb Enara TME-specific T-regs PROTACs Novel antigen discovery 4
Transforming cancer care requires a diversity of minds Example of clinical collaborations Sarah Cannon Research Institute MD Anderson Cancer Center T-cell engagers GI and lung cancers OSE Immunotherapeutics SIRP myeloid checkpoint inhibitor NCC Japan JFCR DLL3/CD3 T-cell engager 5
At Boehringer Ingelheim Cancer Care is personal today and for generations For the long-term with a generational commitment Our goal is to deliver life-changing and best-in-class treatments With the aspiration to transform the lives of people with cancer 6 6
